胰腺大范围切除增加骨密度丢失、骨质疏松与骨折风险
本研究采用两部分分析:基于跨国联邦研究网络(FRN)的倾向性评分匹配队列(8080对匹配)及单中心2005—2019年224例胰腺切除患者的回顾性影像分析。结果显示胰腺切除后病理性骨折风险增加2.4倍,骨质疏松/骨软化症及维生素D缺乏风险增加1.4—1.5倍,CT显示术后骨密度下降较历史对照更快(P=0.015)。
要点
- 胰腺切除术后患者病理性骨折风险增加2.4倍(P<0.0001)。
- 术后骨质疏松/骨软化症及维生素D缺乏风险增加1.4—1.5倍(P<0.0001)。
- 高龄、胰腺癌及胰十二指肠切除术与骨密度丢失速率增加相关(各P<0.05)。
核心结论
- 胰腺切除术后患者骨密度丢失及后续骨折风险更高,随着胰腺切除术后存活人群增长,需关注针对性预防以减少这些脆弱患者的骨密度丢失、骨质疏松和骨折,尤其应关注胰腺癌人群。
研究设计与样本
- 两部分分析:基于跨国联邦研究网络(FRN)的大型倾向性评分匹配队列研究,以及单中心回顾性临床与影像数据回顾,纳入术后随访超过3年的胰腺切除患者。
- FRN分析初始识别8423例胰腺切除术后患者并与正常对照进行倾向性评分匹配。
- 单中心回顾性分析纳入2005年至2019年间接受胰腺切除的224例患者,采用时间序列混合效应线性回归模型评估骨密度趋势及相关因素。
主要发现
- FRN分析共纳入8080对倾向性评分匹配患者,胰腺切除术后患者病理性骨折增加2.4倍(P<0.0001)。
- 胰腺切除术后患者骨质疏松/骨软化症及维生素D缺乏增加1.4—1.5倍(P<0.0001)。
- 胰腺切除组维生素D补充更常见(OR=1.4,95%CI:1.28-1.53,P<0.0001)。
- 胰腺切除组特异性骨质疏松/骨软化症治疗(如降钙素、地舒单抗、罗莫佐单抗、阿巴洛肽、特立帕肽)更常见(OR=2.24,95%CI:1.69-2.95,P<0.0001)。
- CT影像回顾分析显示胰腺切除术后骨密度较正常历史对照下降更快(P=0.015);高龄、胰腺癌及胰十二指肠切除术与骨密度丢失速率增加相关(各P<0.05)。
临床怎么用
- 原文结论指出需关注针对性预防以减少胰腺切除术后患者的骨密度丢失、骨质疏松和骨折,尤其应关注胰腺癌人群。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess whether long-term survivors of pancreatic surgery show increased risk to develop impaired bone mineral density, osteoporosis, and vitamin D deficiency. BACKGROUND: Pancreatic resection poses a risk for malabsorption of fat-soluble vitamins and other micronutrients essential for bone mineralization. Here, we evaluated the long-term effects of pancreatic resection on bone mineral density (BMD) and its clinical sequelae. METHODS: This was a 2-pronged analysis of postpancreatectomy patients with a follow-up period >3 years comprising (1) a large, propensity score matched, cohort study based on a multinational federated research network (FRN) and (2) a retrospective single institution review of clinical and radiographic patient data. In the FRN analysis, an initial cohort of 8423 postpancreatectomy patients were identified and propensity score matched with normal controls. The primary endpoint was the 10-year risk of developing osteoporotic pathologic fractures and secondary endpoints included diagnosis of osteoporosis, vitamin D deficiency, and related therapies. The single institution retrospective analysis identified 224 patients who underwent pancreatic resection between 2005 and 2019. BMD was quantified in CT images acquired before and after surgery. BMD trends and related factors were assessed in a time-series mixed-effect linear regression model. RESULTS: A total of 8080 propensity score-matched pairs were included in the FRN analysis. The analysis revealed a 2.4-fold increase in pathologic fractures ( P <0.0001) and 1.4- to 1.5-fold increase in osteoporosis/osteomalacia ( P <0.0001) and vitamin D deficiency ( P <0.0001) in postpancreatectomy patients. Vitamin D supplements were more common in the pancreatectomy group (OR=1.4, 95% CI: 1.28-1.53, P <0.0001), as were specific osteoporosis/osteomalacia treatments such as calcitonin, denosumab, romosozumab, abaloparatide, and teriparatide (OR=2.24, 95% CI: 1.69-2.95, P <0.0001). Retrospective analysis of CT imaging revealed that BMD declined more rapidly following pancreatic resection compared with normal historical controls ( P =0.015). Older age, pancreatic cancer, and pancreaticoduodenectomy were associated with increased rates of BMD loss ( P <0.05, each). CONCLUSIONS: After pancreatic resection, patients are at higher risk for BMD loss and subsequent fractures. As the cohort of pancreatic resection survivorship grows, attention will need to be paid to focused prevention efforts to reduce BMD loss, osteoporosis, and fractures in these vulnerable patients, with specific attention to the pancreatic cancer population.
引用
- Khalilieh S, Iyer A, Hammelef E, et al. Major Pancreatic Resection Increases Bone Mineral Density Loss, Osteoporosis, and Fractures. Ann Surg. 2024. PMID: 38775462. doi:10.1097/SLA.0000000000006326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。